Two hundred with type 1 diabetes benefit from Accu-Chek Solo managed access programme
- More than 200 people with type 1 diabetes in the UK are now using Accu-Chek Solo insulin pump via a Managed Access Programme
- 79% of users rated the device at least 7/10, giving them more control to manage the condition in their day-to-day lives
- Accu-Chek Solo could now help a further 400,000 people, including 29,000 children, living with type 1 diabetes in the UK
Since the launch of the Accu-Chek Solo micropump, 200 people with type 1 diabetes in the UK are now using the device as part of a ‘Managed Access Programme’ benefiting from the latest in insulin delivery system technology.
The Accu-Chek Solo was first introduced to people living with type 1 diabetes in selected areas through the Managed Access Programme. Introducing this new product in a phased manner has allowed for in-depth conversations with both micropump users and their healthcare professionals. It has been possible for feedback to be rapidly incorporated to continually improve the product and service offering.
Following success of this initial stage, the Accu-Chek Solo could now help a further 400,000 people, including 29,000 children, living with type 1 diabetes in the UK.1 After six weeks, 79% of users rated the device as seven or above out of ten enabling them to have more control in managing their diabetes.2
Providing more control for people with diabetes
One parent, whose daughter has now been using the micropump via the managed access programme, said:
“You only have to change it every three days. Application is easy and fairly painless and you can’t see any needles. Insulin is easily calculated and administered, and doses are easily changed and managed. Blood glucose control and HbA1 results are better and you never forget to take insulin out with you. It has had a huge impact on her mental health and she feels more like her friends at school. My list is endless - it’s super! We love it.”
Roz Hill, Market Manager at Roche Diabetes Care said, “This important milestone means people living with type 1 diabetes, who could benefit from this therapy option, can spend more time in their ideal target glucose range and experience an improved quality of life. The new modular design of the Accu-Chek Solo micropump system responds to the needs of people with diabetes with more discretion and flexibility.”
Convenient and personalised for effective management
The Accu-Chek Solo micropump system allows for convenience and personalisation in insulin pump therapy while contributing to a more targeted and effective diabetes management. It offers the functionalities of a traditional insulin pump alongside with the technological advancement of tube-free insulin delivery. The system consists of two parts: a small, lightweight and semi-disposable insulin micropump and a fully- featured remote control incorporating blood glucose monitoring and bolus advice. The system provides bolus insulin dosing both from the remote control or directly from the pump as well as the option to detach and re-attach the pump without wasting insulin. In addition, the system connects to Roche Diabetes Care’s digital solutions such as the Accu-Chek Smart Pix system, providing decision and therapy support at the doctor’s office with a proven tool for efficient, effective and personalised diabetes management.3,4
- JDRF. Type 1 diabetes facts and figures [online] 2018. Available from: https://jdrf.org.uk/information-support/about-type-1-diabetes/facts-and-figures/ [Last accessed: June 2019]
- Roche. Accu-Chek customer survey data [online] 2019. Available from: https://www.netigate.se/tool/Default.aspx?page=30&pa=1&rs=3ed1e07b-27f0-4453-9d14-131161c4ff6b&share=5f27f199-8cc9-4ad0-8c73-081524e48e28 [June 2019]
- Weissmann, J. et al.; J Diabetes Sci Technol. 2015 Jul 29;10(1):76-84
- Dänschel I., Dänschel W., Heinemann L., Weissmann J., Kulzer, B.: Effects of integrated Personalized Diabetes Management: Results of the PDM - ProValue study program. Poster (1261) at the 15th International Primary Care Diabetes Europe Conference, 13–14 April 20p8, Barcelona, Spain.